President Trump’s highly publicized executive order 14297, titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” targets the discrepancy in drug pricing in the United States compared with...more
5/16/2025
/ Antitrust Provisions ,
Department of Health and Human Services (HHS) ,
Direct to Consumer Sales ,
Drug Pricing ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
International Trade ,
Most-Favored Nations ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Requirements ,
Trump Administration ,
U.S. Commerce Department
President Trump’s May 5, 2025, executive order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines” sets out the administration’s goals to increase the domestic manufacture of critical...more
5/8/2025
/ Country of Origin ,
Drug Pricing ,
Environmental Policies ,
Environmental Protection Agency (EPA) ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
Life Sciences ,
Manufacturers ,
Manufacturing Facilities ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Reform ,
Supply Chain ,
Trump Administration
In FDA v. Wages and White Lion Investments LLC, the U.S. Supreme Court’s unanimous decision in favor of the Food and Drug Administration serves as a reminder of the deference still accorded to regulatory agencies post-Loper...more
4/21/2025
/ Administrative Procedure Act ,
Appeals ,
E-Cigarettes ,
FDA Approval ,
FDA v Wages and White Lion Investments LLC ,
Food and Drug Administration (FDA) ,
Judicial Authority ,
Popular ,
Regulatory Agencies ,
Rulemaking Process ,
SCOTUS ,
Tobacco Regulations ,
Vaping